The overall increase of oxidative stress in diabetes may not only result from increased generation of ROS, but also from compromised inhibitory and scavenging mechanisms. For example, endogenous antioxidant and scavenging protectors such as vitamin E and glutathione are depleted in diabetes and antioxidant enzymes such as superoxide dismutase and catalase are less active [15] [16] [17] [18] .
Based on these experimental observations, it has been postulated that diabetic retinopathy may be amenable to antioxidant treatment [10, 14] . However, only preliminary experiments are available showing that probucol -a lipid lowering and antioxidant compound -ameliorates disturbed vascular permeability in the retinae of short-term diabetic rats [19] .
Therefor, the aim of this study was to evaluate the effect of a new antioxidant compound, 2,6-Di-tert-butyl-4-[3-(3-pyridylmethoxy)propyl]phenol (nicanartine), on histological parameters of experimental retinopathy in the long-term streptozotocin (STZ)-diabetic rat. Nicanartine was primarily developed as an antiatherogenic drug, characterized by lipid-lowering, potent antioxidant and antiproliferative properties [20] . In non-diabetic rats, the compound lowers triglyceride levels more efficiently than probucol. It strongly inhibits cell-and Cu 2 + -induced lipid peroxidation of LDL with an IC 50 of less than 5 m mol. HDL and VLDL fractions are also protected against lipid peroxidation. In vivo experiments in hypercholesterolaemic rabbits confirmed the in vitro data by showing that the susceptibility of lipoproteins to oxidative stress is greatly diminished. Nicanartine also inhibits smooth muscle cell proliferation after balloon catheter-induced endothelial injury and improves vascular reactivity as reflected by an increased response to acetylcholine-induced dilatation in cholesterol-fed and Watanabe rabbits [20] [21] [22] .
Materials and methods
Animals. The use of animals in this study conformed to the Association for Research in Vision and Ophthalmology Resolution on the Use of Animals in Research.
Six-week-old inbred Lewis rats weighing 202.8 ± 11.7 g were used in the study (Zentralinstitut fü r Versuchstierkunde, Hannover, Germany). Chemical diabetes was induced by i. v. injection of streptozotocin (65 mg/kg body weight; Boehringer Mannheim, Mannheim, Germany). After confirmation of stable hyperglycaemia (blood glucose level > 15 mmol/l, 5 days after STZ injection), diabetic animals were randomly assigned to receive either standard rodent chow containing nicanartine (80 mg ⋅ kg body weight ; D-N; n = 8) or no treatment (DC; n = 6). Dosage of nicanartine was adjusted according to food consumption and body weight of the individual animals. According to in vivo studies in rats, nicanartine is readily absorbed after a single oral administration, with a peak plasma concentration of 1 mg/l after 1.5-2 h returning to baseline after 6 h [20] . Eight non-diabetic animals served as controls (NC).
All animals in the two diabetic groups received 1-2 IU of NPH insulin s. c. twice weekly to prevent critical weight loss (less than 180 g) only during the first month after diabetes induction. Thereafter, insulin injections (1 IU) were given only occasionally, indicating stabilization of weight in both diabetic groups. No insulin was given during the last month of the experimental period.
Blood glucose, body weight and glycated haemoglobin (boronate affinity chromatography; Glyc Affin GHb, DRG, Marburg, Germany) were measured at regular intervals. Cholesterol and triglycerides were monitored at different time points. Blood was obtained at the end of the study to measure plasma concentrations of the drug and thiobarbituric acid reactive substances (TBARS) [23] .
Retinal analysis. Retinae were obtained at the end of the study after enucleation of the eyes from the animals under deep anaesthesia and were immediately fixed in 4 % buffered formalin.
Retinal vascular preparations were performed using a pepsin-trypsin digestion technique as previously described [24] . Briefly, a combined pepsin (5 % pepsin in 0.2 % hydrochloric acid for 1.5 h) trypsin (2.5 % in 0.2 mol/l Tris for 15-30 min) digestion was used to isolate the retinal vasculature. Unstained preparations were used to measure autofluorescent advanced glycated end-products (AGE) by an established method [24, 25] . Although peroxidation products share with AGE the propensity of fluorescence, their excitation/emission wavelengths are different [26] . Subsequently, the samples were stained with periodic acid Schiff.
Acellular capillaries were quantitated using a grid of 100 fields, with which 10 microscopic fields covering a total area of 6.76 mm 2 of retinal area were scored for the presence of acellular occluded vessels (integration ocular Olympus/ 400 × magnification). Each field containing acellular capillary segments was recorded as positive, and values were normalized to mm 2 of retinal area. The total number of endothelial cells and pericytes was counted in ten randomly selected fields of the retina using an image analysing system (CUE 2; Olympus Opticals Inc., Hamburg, Germany). The numbers of both capillary cell types were normalized to the relative capillary density (numbers of cells per mm 2 of capillary area). Retinae were completely evaluated for the total number of microaneurysms.
Immunohistology. Vertical cryostat sections of the contralateral eyes were scored for the expression of heme oxygenase I (HO-1; HSP 32) as an indicator of intracellular oxidative stress [27] . Briefly, tissue sections (5-7 m m) were cut on a cryostat at -20°C and placed on poly-lysine coated slides. After fixation with 96 % (w/v) acetone for 5 min, slides were air-dried, subsequently washed with 0.1 mol/l phosphate-buffered saline (PBS) and blocked with PBS containing 3 % (w/v) bovine serum albumin. A polyclonal anti-HO-1 antibody (raised against rat liver HO-1 (27); 1: 100; Stressgene, Dianova, Hamburg, Germany) was incubated with serial sections for 45 min at 22°C. Slides were rinsed twice with PBS buffer and exposed to a fluoresciene isothiocyanate (FITC)-conjugated rabbit-anti-murine antibody (1:20; DAKO, Hamburg, Germany). Sections were rinsed again, coverslipped, and examined using an epifluorescence microscope (Olympus). Control slides were included by replacing the primary antibody with nonimmune murine IgG.
Statistical analysis
All parameters are given as mean ± SD. For statistical analysis, analysis of variance (ANOVA) and the Bonferroni multiple comparison test (Instat; GraphPad, San Diego, Calif., USA) were used.
Results
Blood glucose, body weight, and glycated haemoglobin were comparable in untreated and treated diabetic animals and significantly different from non-diabetic controls (Table 1 ). The administration of nicanartine had no effect on overall glycaemia in diabetic rats. No change in total and HDL cholesterol levels of the treated diabetic group was observed. However, nicanartine reduced the threefold elevated level of triglycerides in untreated diabetic rats by 22 % (p < 0.001). Plasma TBARS were used as a marker of increased extracellular oxidative stress. Hyperglycaemia slightly increased plasma TBARS without reaching statistical significance. The levels remained unaffected by antioxidant treatment (Table 1) .
Consistent with the pharmakokinetics of nicanartine, plasma levels were undetectable after a 12-h fasting period, as measured at the time the animals were killed.
The effect of the treatment was studied on the level of a retinal marker of intracellular oxidative stress, heme-oxygenase-1 (HO-1). While in DC (Fig. 1 b) , a major increase of HO-1 immunoreactivity was observed both in vascular and non-vascular retinal tissue compared with non-diabetic controls ( Fig. 1 a) ; vascular immunolabelling was greatly reduced in nicanartine treated animals, indicating a specific effect of nicanartine on the vasculature in diabetes (Fig. 1 c) .
To test whether treatment with nicanartine would reduce the formation and accumulation of AGEs, we studied autofluorescent AGEs in retinal digests. No major difference in the amount of accumulated AGEs was discernible between treated and untreated diabetic groups (Table 2) .
Chronic hyperglycaemia for 6 months in STZ-diabetic rats led to a 37.3 % increase of retinal capillary endothelial cells (NC vs DC p < 0.001). Treatment with nicanartine significantly reduced endothelial proliferation by 34.4 % (p < 0.001 vs DC) ( Table 2) .
Pericyte loss is the most characteristic and earliest morphological change in experimental diabetic retinopathy. In the diabetic group, a 26.6 % reduction of pericyte numbers was observed. Nicanartine significantly diminished pericyte loss by 41.0 %, compared with DC (p < 0.001). The resultant E/P ratio, which reflects total capillary cell composition independent of individual changes, was almost 1:1 (1.13 ± 0.16) in non-diabetic rats. Due to both endothelial proliferation and pericyte loss, the E/P ratio was significantly increased in the DC group (2.14 ± 0.37; p < 0.001 vs NC). Treatment with nicanartine significantly ameliorated the E/P ratio (1.66 ± 0.22; p < 0.001 vs DC).
Diabetic rats had a 3.1-fold increase in occluded capillaries (DC 86.2 ± 9.01 acellular capillaries/mm 2 of retinal area vs NC 27.4 ± 14.0 acellular capillaries/ mm 2 of retinal area). In comparison with untreated diabetic rats, in diabetic animals treated with nicanartine there was no difference in their numbers of acellular capillaries (D-N 73.0 ± 14.75) ( Table 2) .
The same finding applied to the occurrence of microaneurysms. While no microaneurysms were observed in non-diabetic groups, a small but equal number of microaneurysms was present in both diabetic groups.
Discussion
The assumption that antioxidants may prevent retinopathy in diabetes was based on studies showing increased generation of ROS under hyperglycaemic conditions and the toxicity of these products for microvascular cells in vitro [7, 10, 14] . However, our study demonstrates that antioxidant treatment has only a limited beneficial effect on diabetes-induced The antioxidant potency of nicanartine on in vitro lipid peroxidation has been reported to be higher than vitamin E, especially in the VLDL fraction, and nicanartine inhibits endothelial-induced LDL oxidation more effectively than probucol, as measured by TBARS [20] . These data indicate that, in general, nicanartine is a potent antioxidant compound.
The efficacy of an antioxidant compound may vary in vivo due to its local bioactivity. There is biochemical as well as histological evidence that the dosage of nicanartine which was derived from previous experiments in rats was effective [20] . Hyperglycaemia-induced increased trigyceride levels were significantly lowered by nicanartine, indicating a biochemical effect of the compound. Diabetes induced an increased expression of retinal HO-1, a substitute marker for retinal intracellular oxidant stress in our model and this cellular response to increased oxidative stress was reduced by nicanartine. Heme oxygenase I (EC 1.14.99.3) is a regulatory enzyme in the heme degradative pathway that catalyses the oxidation of heme into biliverdin and CO [27] . A variety of processes can cause increased intracellular production of ROS in the retina, which uniformly lead to an upregulation of HO-1 as an indicator of increased intracellular oxidant stress [28] [29] [30] . As one example, retinal oxidant stress with HO-1 expression is induced in rats by exposure to intense visible light and is suppressed by antioxidant treatment [31] . Evidently, chronic hyperglycaemia induces similar cellular responses in the diabetic retina, but the cause for the moderate inhibitory effect of nicanartine on experimental retinopathy remains obscure. Consistent with our findings is the recent report by Kowluru et al. [32] , showing that 2 months of antioxidant supplementation with 1 % ascorbic acid and 0.1 a c Fig. 1 a-c . Effect of nicanartine on the expression of heme oxygenase 1. Microphotographs show representative horizontal sections through the inner nuclear layer parallel to the inner limiting membrane, composed of neuroglial and vascular structures. (a) non-diabetic, (b) untreated diabetic, (c) diabetic, treated with nicanartine. Note the increased expression of heme oxygenase-1 both in vascular (white arrow) and nonvascular structures of untreated diabetic rats (Fig. 1 b) . Original magnification 400 × b a -tocopherol acetate lowered retinal TBARS as another measure of retinal oxidant stress.
The failure to detect an increase of TBARS in the plasma of the untreated diabetic rats is not unprecedented and can be explained by the insufficient specificity of this assay [33] [34] [35] . Among other reasons for this observation, it is possible that extracellular peroxidation products as measured by TBARS in diabetic rats are only transiently elevated [36] . Thus, data from our study together with reported findings suggest that the major permanent site of oxidant stress is intracellular.
In addition to its generation from glucose autoxidation and propagation through glycated proteins, another origin of intracellular oxidant stress in diabetic tissues is the interaction of specific cellular receptors with AGE in the matrix [28] . The activation of NF-kappaB, a pleiotrophic transcription factor, and of HO-1 have been observed, associated with cellular dysfunction and damage.
Therefore, the success of any antioxidant treatment may predominantly depend upon the ability of any compound to interfere with intracellular ROS formation.
Very recently, experiments using supplementation of 1 % ascorbic acid and 0.1 % alpha-tocopherol as antioxidant treatment were reported. Diabetic rats treated for 18 months with high doses of antioxidant vitamins showed only a modest effect on diabetic retinopathy. The formation of acellular capillaries was only moderately inhibited, while no effect was found on pericyte loss [37] .
Although the results of that study contrast with data from our study with respect to the parameters affected by antioxidant treatment, they favour an alternative conclusion, which is that oxidative stress may not be a major cause of diabetic retinopathy. However, as with the study presented here, it may still be that antioxidants available so far are too weak to compensate for the retinal injury caused by hyperglycaemia-induced intracellular oxidant stress. Supporting such conclusions, experimental studies in diabetic rats revealed an acceleration of retinopathy as measured by a 75 % increase of acellular occluded capillaries as the result of oral fish oil supplementation over a 6-month period [38] .
Experimental evidence also suggests that the relative contribution of oxidative products accessible for antioxidant treatments is tissue-specific. While Soulis-Liparota et al. [33] were unable to detect any significant effect of probucol on albuminuria in STZ-diabetic rats over 32 weeks, Cameron et al. [39] reported a significant effect of probucol on nerve conduction velocity and nerve blood flow as early as after 1 and 2 months of diabetes, even in the presence of the pro-oxidant compound primaquine. Studies in experimental diabetic retinopathy using 1 % probucol supplementation to the rat chow yielded comparable results to those of the present study with nicanartine [40] .
Results from this study should not be extrapolated to human diabetes without caution, especially due to the more severe diabetic state of the animals studied and to the differences in lipid metabolism between rodents and humans [41, 42] . With the development of stronger antioxidant compounds which preferably should be targeted to interfere with increased intracellular oxidative stress, we anticipate that the true role of oxidation in the pathogenesis of diabetic retinopathy is assessable. Moreover, a subset of diabetic patients may exist in which the relative contribution of oxidative damage to the development of complications is mainly due to factors such as inherited impairment of defence systems or environmental/nutritional factors. In these cases, treatment using available antioxidants may deserve further consideration.
